Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + olverembatinib + blinatumomab + chidamide
- Development stage
- Preclinical
- Lead developer
- Ascentage Pharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of prednisone (a corticosteroid), olverembatinib (a third-generation BCR-ABL tyrosine kinase inhibitor), blinatumomab (a bispecific T-cell engager antibody), and chidamide (a histone deacetylase inhibitor). This regimen likely combines multiple mechanisms of action to target hematological malignancies, particularly leukemias that may be resistant to standard therapies.
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)GR (Glucocorticoid receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)SFK (SRC family kinases)MR (Mineralocorticoid receptor)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on prednisone + olverembatinib + blinatumomab + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + olverembatinib + blinatumomab + chidamide.